Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?

Roobol MJ.

Eur Urol. 2018 Oct 25. pii: S0302-2838(18)30809-1. doi: 10.1016/j.eururo.2018.10.021. [Epub ahead of print] No abstract available.

PMID:
30482669
2.

Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

JAMA Oncol. 2017 Oct 1;3(10):1393-1398. doi: 10.1001/jamaoncol.2016.3600.

3.

Active surveillance in men with low-risk prostate cancer: current and future challenges.

Han CS, Parihar JS, Kim IY.

Am J Clin Exp Urol. 2013 Dec 25;1(1):72-82. eCollection 2013. Review.

4.

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J.

Eur Urol. 2016 Nov;70(5):760-766. doi: 10.1016/j.eururo.2016.03.048. Epub 2016 Apr 16.

PMID:
27090975
5.

Active Surveillance for Prostate Cancer: How to Do It Right.

Garisto JD, Klotz L.

Oncology (Williston Park). 2017 May 15;31(5):333-40, 345. Review.

6.

Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer.

Carter HB.

Curr Opin Urol. 2015 May;25(3):277-82. doi: 10.1097/MOU.0000000000000153. Review.

PMID:
25692722
7.

Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.

Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM.

Eur Urol. 2018 Nov 10. pii: S0302-2838(18)30853-4. doi: 10.1016/j.eururo.2018.10.055. [Epub ahead of print]

PMID:
30425010
8.

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group.

Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.

9.

Our results of active surveillance for localized prostate cancer patients.

Soydan H, Dursun F, Yılmaz Ö, Okçelik S, Ateş F, Karademir K.

Turk J Urol. 2013 Mar;39(1):1-5. doi: 10.5152/tud.2013.001.

10.

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.

JAMA. 2010 Dec 1;304(21):2373-80. doi: 10.1001/jama.2010.1720. Erratum in: JAMA. 2011 May 11;305(18):1862.

11.

Active surveillance in Canadian men with low-grade prostate cancer.

Cristea O, Lavallée LT, Montroy J, Stokl A, Cnossen S, Mallick R, Fergusson D, Momoli F, Cagiannos I, Morash C, Breau RH.

CMAJ. 2016 May 17;188(8):E141-7. doi: 10.1503/cmaj.150832. Epub 2016 Feb 29.

12.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

13.

Rethinking active surveillance for prostate cancer in African American men.

Leinwand GZ, Gabrielson AT, Krane LS, Silberstein JL.

Transl Androl Urol. 2018 Sep;7(Suppl 4):S397-S410. doi: 10.21037/tau.2018.06.19. Review.

14.

Racial Disparities in Active Surveillance for Prostate Cancer.

Krishna S, Fan Y, Jarosek S, Adejoro O, Chamie K, Konety B.

J Urol. 2017 Feb;197(2):342-349. doi: 10.1016/j.juro.2016.08.104. Epub 2016 Sep 3.

PMID:
27596691
15.

An integrative review of nursing research on active surveillance in an older adult prostate cancer population.

Madsen L, Symes L.

Oncol Nurs Forum. 2013 Jul;40(4):374-82. doi: 10.1188/13.ONF.40-04AP. Review.

PMID:
23823629
16.

Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.

Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J.

Eur Urol. 2017 Oct;72(4):534-541. doi: 10.1016/j.eururo.2016.10.031. Epub 2016 Nov 2.

17.

Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.

Tsang CF, Tsu JH, Lai TC, Wong KW, Ho BS, Ng AT, Ma WK, Yiu MK.

Hong Kong Med J. 2017 Dec;23(6):609-15. doi: 10.12809/hkmj166194. Epub 2017 Oct 13.

18.

Active surveillance or active treatment in localized prostate cancer?

Weissbach L, Altwein J.

Dtsch Arztebl Int. 2009 May;106(22):371-6. doi: 10.3238/arztebl.2009.0371. Epub 2009 May 29. Review.

19.

Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.

Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC; Michigan Urological Surgery Improvement Collaborative.

Eur Urol. 2015 Jan;67(1):44-50. doi: 10.1016/j.eururo.2014.08.024. Epub 2014 Aug 24.

PMID:
25159890
20.

Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?

Radomski L, Gani J, Trottier G, Finelli A.

Can J Urol. 2012 Jun;19(3):6287-92.

PMID:
22704315

Supplemental Content

Support Center